ImmuCell Corporation (ICCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmuCell Corporation (ICCC) has a cash flow conversion efficiency ratio of 0.096x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.02 Million) by net assets ($31.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ImmuCell Corporation (ICCC) total market value for the company's overall valuation and market capitalisation.
ImmuCell Corporation - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how ImmuCell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ImmuCell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuCell Corporation ranked by their cash flow conversion efficiency. Explore ICCC cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CeoTronics AG
F:CEK
|
0.061x |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
0.014x |
|
KUYA SILVER CORP.
F:6MR1
|
-0.023x |
|
Edel SE & Co. KGaA
F:EDL
|
0.113x |
|
Hyosung Itx
KO:094280
|
0.371x |
|
ChampionsGate Acquisition Corporation Class A Ordinary Share
NASDAQ:CHPG
|
0.000x |
|
Petrolimex Insurance Corp
VN:PGI
|
0.063x |
|
AUGUSTA GOLD DL-0001
F:7RZ
|
N/A |
Annual Cash Flow Conversion Efficiency for ImmuCell Corporation (1989–2025)
The table below shows the annual cash flow conversion efficiency of ImmuCell Corporation from 1989 to 2025. View ImmuCell Corporation share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.06 Million | $2.48 Million | 0.091x | +603.45% |
| 2024-12-31 | $27.52 Million | $357.90K | 0.013x | +106.95% |
| 2023-12-31 | $24.99 Million | $-4.67 Million | -0.187x | -268.02% |
| 2022-12-31 | $30.38 Million | $-1.54 Million | -0.051x | -273.50% |
| 2021-12-31 | $32.58 Million | $954.17K | 0.029x | -37.07% |
| 2020-12-31 | $28.27 Million | $1.32 Million | 0.047x | +477.85% |
| 2019-12-31 | $28.99 Million | $233.51K | 0.008x | +146.90% |
| 2018-12-31 | $21.74 Million | $-373.40K | -0.017x | -134.46% |
| 2017-12-31 | $23.59 Million | $1.18 Million | 0.050x | +403.43% |
| 2016-12-31 | $19.72 Million | $-323.90K | -0.016x | -106.01% |
| 2015-12-31 | $10.61 Million | $2.90 Million | 0.273x | +736.69% |
| 2014-12-31 | $9.26 Million | $302.36K | 0.033x | -72.07% |
| 2013-12-31 | $9.40 Million | $1.10 Million | 0.117x | +212.19% |
| 2012-12-31 | $9.19 Million | $344.39K | 0.037x | +1005.44% |
| 2011-12-31 | $9.02 Million | $-37.31K | -0.004x | +95.25% |
| 2010-12-31 | $9.28 Million | $-808.61K | -0.087x | -664.32% |
| 2009-12-31 | $9.62 Million | $-109.67K | -0.011x | -306.85% |
| 2008-12-31 | $9.64 Million | $53.14K | 0.006x | -84.15% |
| 2007-12-31 | $10.06 Million | $349.56K | 0.035x | -76.12% |
| 2006-12-31 | $9.33 Million | $1.36 Million | 0.146x | +62.84% |
| 2005-12-31 | $8.56 Million | $764.78K | 0.089x | -49.14% |
| 2004-12-31 | $7.73 Million | $1.36 Million | 0.176x | -7.76% |
| 2003-12-31 | $7.37 Million | $1.40 Million | 0.190x | -30.22% |
| 2002-12-31 | $6.95 Million | $1.90 Million | 0.273x | +82.16% |
| 2001-12-31 | $6.05 Million | $906.00K | 0.150x | +918.37% |
| 2000-12-31 | $5.54 Million | $81.50K | 0.015x | -93.90% |
| 1999-12-31 | $2.82 Million | $679.70K | 0.241x | -11.48% |
| 1998-12-31 | $2.20 Million | $600.00K | 0.273x | +527.27% |
| 1997-12-31 | $2.30 Million | $100.00K | 0.043x | +182.61% |
| 1996-12-31 | $1.90 Million | $-100.00K | -0.053x | -133.33% |
| 1995-12-31 | $1.90 Million | $300.00K | 0.158x | +400.00% |
| 1994-12-31 | $1.90 Million | $-100.00K | -0.053x | -221.05% |
| 1993-12-31 | $2.30 Million | $100.00K | 0.043x | +126.09% |
| 1992-12-31 | $1.80 Million | $-300.00K | -0.167x | +79.17% |
| 1991-12-31 | $1.50 Million | $-1.20 Million | -0.800x | -348.00% |
| 1990-12-31 | $2.80 Million | $-500.00K | -0.179x | -1.19% |
| 1989-12-31 | $3.40 Million | $-600.00K | -0.176x | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more